Ivermectin Mass Drug Administration for Malaria Elimination in the Greater Mekong Subregion
|
|
- Michael Martin
- 5 years ago
- Views:
Transcription
1 ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES ( AFRIMS) Ivermectin Mass Drug Administration for Malaria Elimination in the Greater Mekong Subregion Kevin Kobylinski*, Silas Davidson, Jason Richardson, Wes McCardle, Alongkot Ponlawat, Ratawan Ubalee, Siriporn Phasomkusolsil, Brian Foy, Podjanee Jittamala, Sasithon Pukrittayakamee, Borimas Hanboonkunupakarn, Rob van der Pluijm, Mavuto Mukaka, Thanaporn Wattanakul, Richard Hoglund, Joel Tarning, Arjen Dondorp, Nick Day, Nick White * Kevin.kobylinski.gst@afrims.org Principal Investigator, The Geneva Foundation (6 December 2017) JITMM The views expressed in this presentation are those of the authors and do not reflect the official policy of the Department of Army, Department of Defense, nor the U.S. Government. Trade names are used for identification purposes only and do not imply endorsement. UNCLASSIFIED 1
2 Ivermectin - background Endectocide activity against internal and external parasites Macrocyclic lactone isolated from the bacteria Streptomyces avermitilis Mode of action binds at subunit interfaces next to the glutamategated chloride (GluCl) ion channels, which distorts the channel from closed to open, hyperpolarizing the cell (Hibbs and Gouaux 2011) which leads to the paralysis of the nematode or ectoparasite musculature (Cully et al. 1994, 1996, Cane et al. 2000) Lethal against Anopheles mosquitoes! Different class of insecticides than those used for ITNs or IRS (Omura and Crump 2004) UNCLASSIFIED 2
3 Ivermectin - Neglected Tropical Diseases Onchocerciasis Onchocerca volvulus Lymphatic filariasis Wuchereria bancrofti, Brugia malayi, and Brugia timori ->300 million people given ivermectin mass drug administration (MDA) annually - 11/13 onchocerciasis foci in Latin America eliminated (x1-4 MDAs/year) Ascariasis Ascaris lumbricoides Trichuriasis Trichuris trichiura Strongyloidiasis Strongyloides stercoralis - Currently approved treatment in Thailand (oral 200 μg/kg) Pediculosis Pediculus humanus humanus and P. h. capitus Scabies Sarcoptes scabei - One person treated 150 times in 13 years, 12 times in 1 month (Mounsey et al. 2008) - Safe in healthy volunteers up to 2000 μg/kg (Guzzo et al. 2002) UNCLASSIFIED 3
4 MDA by Community Directed Treatment with Ivermectin (CDTI) UNCLASSIFIED 4
5 AFRICA An. gambiae s.s. (Fritz et al. 2009, Sylla et al. 2010, Chaccour et al. 2010, Kobylinski et al. 2010, 2012, 2014, Butters et al. 2012, Ouédraogo et al. 2015, Alout et al. 2014, Derua et al. 2015, 2016, Seaman et al. 2015) An. arabiensis (Fritz et al. 2009, 2012, Yamada et al. 2013) An. coluzzi (Poché et al. 2015) An. funestus (Ouédraogo et al. 2015) SOUTH PACIFIC An. farauti (Foley et al. 2000, Kositz et al. 2017) An. punctulatus (Bockarie et al. 1999) ASIA An. stephensi (Pampiglione et al. 1985, Iakubovich et al. 1989, Naz et al. 2013, Bastiens et al. 2012) An. culicifacies (Naz et al. 2013) An. sacharovi (Iakubovich et al. 1989) GREATER MEKONG SUBREGION An. dirus (Kobylinski et al. 2017a) An. minimus (Kobylinski et al. 2017a) An. sawadwongporni (Kobylinski et al. 2017a) An. campestris (Kobylinski et al. 2017a) AMERICAS An. quadrimaculatus (Jones et al. 1992, Gardner et al. 1993) An. aquasalis (Sampaio et al. 2016, 2017) An. darlingi (Kobylinski et al. 2017b) UNCLASSIFIED 5
6 In vitro estimated ivermectin lethal concentrations in Anopheles = LC 50 = LC 25 = LC 5 (Kobylinski et al. 2017a) (Kobylinski et al. 2010) (Kobylinski et al. 2017b) dirus sawadwongporni campestris minimus gambiae darlingi aquasalis n=5029, r=6 n=1431, r=4 n=2786, r=4 n=2376, r=6 n=2013, r=8 n=6061, r=13 n=1415, r=5 (5-day LC 50 ) (5-day LC 50 ) UNCLASSIFIED (Sampaio et al. 2016) 6
7 Population age structure shift numbers numbers of of females females = 0.7 P = 0.85 x 0.2 x = 0.2 all females all females infective females infective females V = 0 0 ma 2 p n b -lnp days days p daily probability of adult mosquito survivorship Vectorial Capacity Equation (Garrett-Jones 1964, Black and Moore 2005) UNCLASSIFIED 7
8
9 Entomology Field Results Senegal 2008 Aug Senegal 2009 Aug. Senegal 2009 Oct. Liberia 2013 Jun. Burkina Faso 2013 Aug. - -MDA coverage 76-84% - ITN coverage 38-82% Senegal 2012 Aug. Burkina Faso 2013 Aug. V = ma 2 p n b -lnp Senegal 2012 Aug. Liberia 2013 Jun. Burkina Faso 2013 Aug. Sporozoite rate Time relative to MDA (days) V average number of potentially infective bites that will be delivered by all vectors feeding on a single host in one day (Alout et al. 2014, Sylla et al. 2010, Kobylinski et al. 2011)
10 Anopheles LC 50 ( ) and LC 25 ( ) values plotted on PK model estimates Ivermectin concentration (ng/ml) (Alout et al. 2014) Time (hours) (Kobylinski et al. 2017a) 200 μg/kg 400 μg/kg 800 μg/kg dirus sawadwongporni campestris minimus gambiae darlingi aquasalis
11 Targeted Malaria Elimination - MDAs with dihydroartemisinin-piperaquine and primaquine reduce infectious human reservoir and prevent onwards transmission from treated individuals - However, primaquine has no effect on oocysts or sporozoites in already infected mosquitoes (Coleman et al. 1994), so there will be NO IMMEDIATE effect on mosquito-to-human transmission - Ivermectin MDA targets the vector with mosquito-lethal endectocides which IMMEDIATELY suppresses mosquito-to-human transmission (Sylla et al. 2010, Kobylinski et al. 2011, Alout et al. 2014) - Ivermectin MDA would reduce number of new infections in treated and UNTREATED persons - Disparate modes of action on transmission make ivermectin plus primaquine MDA ideal - Direct personal benefits are observed during ivermectin MDAs (Okeibunor et al. 2011), therefore, combining ivermectin with antimalarial MDAs may enhance compliance
12 Ivermectin & Eurartesim Clinical Trial Open-Label Study to Evaluate Safety, Tolerability, Potential Pharmacokinetic Interaction and Mosquito-Lethal Effects of Orally Administered Ivermectin, Primaquine, Dihydroartemisinin-Piperaquine, and Albendazole in Healthy Adult Subjects NCT [TMEC , OxTREC 4-15, WRAIR#2228] Collaboration between Mahidol University, MORU, and AFRIMS Dr. Podjanee Jittamala (Principal Investigator) Sequential trial in healthy Thai adults (x16 7M:9F) Determine safety, tolerability, pharmacokinetic interaction, and mosquito-lethal efficacy of single doses: 1) Ivermectin (Vermectin, Atlantic Laboratories (400 µg/kg)) 2) Ivermectin + Primaquine (Primaquine Phosphate, Thai GPO (30 mg)) 3) Ivermectin + Dihydroartemisinin-Piperaquine (Eurartesim, Sigma-Tau (120/960 mg)) 4) Ivermectin + Dihydroartemisinin-Piperaquine + Primaquine 5) Primaquine 6) Dihydroartemisinin-Piperaquine 7) Dihydroartemisinin-Piperaquine + Primaquine UNCLASSIFIED 12
13 Non-compartmental pharmacokinetic interactions of ivermectin The exposure (AUC 0-T and C max ) of ivermectin is slightly increased when co-administrated with primaquine (PQ) A significant increase in ivermectin exposure observed when co-administrated with dihydroartemisinin-piperaquine (DHA-PQP) A significant additive increase in exposure observed when co-administrated with DHA-PQP and PQ IVM + PQ IVM + DHA-PQP IVM + DHA-PQP + PQ UNCLASSIFIED (Tarning, unpublished data) 13
14 Mosquito Survival Studies 1) Venous whole blood collected at Mahidol Healthy Volunteer Ward from volunteers in sodium heparin tubes 2) Collected before and post drug ingestion at 0, 4, 24 hours, and 2, 3, 6, 10 days post dose 3) Blood (600µl) membrane fed at 37ºC to An. dirus and An. minimus (x100 each) 4) x40 blood-fed of each species saved for survival monitoring at 25ºC, 80% r.h. 5) Daily mosquito survival monitoring for ten days post blood meal Volunteer sample collection timeline (days)
15 Ivermectin (400 μg/kg) mosquito survivorship results Anopheles dirus Anopheles minimus Hours (days) of blood collection Volunteer sample collection timeline (days) (Kobylinski, unpublished data)
16 Mean mortality (95% CI) of An. dirus after volunteer blood ingestion by regimen 100 Mosquito mortality (%) Combination with DHA-PQP enhances mosquito-lethal efficacy (1) 48(2) 72(3) 144(6) 240(10) Hours (days) since drug ingestion by volunteer - SMFAs with An. dirus and piperaquine compound showed no mortality effect (1-100,000 ng/ml) (Kobylinski, unpublished data)
17 An. dirus mortality following ingestion of ivermectin spiked blood or ivermectin-administered volunteer blood (7 days) Ivermectin-spiked blood Volunteer blood LC 50 = 56.9 [ ] (ng/ml) Reps = 6, mosq = 5,029 LC 50 : all regs = [ ] (ng/ml) IVM only = [ ] (ng/ml) Vols = 16 mosq = 17,946 mosq = 4,477 (Kobylinski et al. 2017) LC 50 s estimated using a normalized concentration-response analysis (IC 50, Hill) LC 50 with volunteer blood is x20 fold lower than ivermectin-spiked blood, possibly due to metabolites with mosquito-lethal activity Recent award from the Bill & Melinda Gates Foundation to characterize ivermectin metabolites and their impact on mosquito survival (Kobylinski, unpublished data)
18 Clinical Results Change QTcF-values between H0 and H4 No QTc-interval >500 ms, and change from baseline >60 ms (FDA limit) 1/16 volunteers had transient elevations of AST (x ULN) and ALT (x5 ULN) when Ivermectin and DHA-PQP co-administered Combinations well tolerated dqtcfridericia (ms) FDA treshold No safety concerns with ivermectin and primaquine (30mg) Ongoing trial in Kenya will investigate combination of ivermectin and DHA-PQP in 141 falciparum patients DHA-PQP PQ IVM IVM+PQ DHA-PQP+PQ DHA-PQP+IVM DHA-PQP+IVM+PQ (Jittamala, unpublished data)
19 Ivermectin (LC 25 ) sporontocidal to P. falciparum NF54 in An. gambiae * * LC 25 = 10.7 ng/ml * V = ma 2 p n b -lnp b vector competence n extrinsic incubation period DDPI Stage 7 Oocyst 12 Sporozoite 14 Sporozoite χ 2 = 15.48, P = χ 2 = 13.47, P = χ 2 = 19.96, P < (F-value = 0.01, P = , n = 233) Plasmodium blood feed Ivermectin blood feed dissection time point (Kobylinski et al. 2012)
20 Ivermectin (LC 25 and LC 5 ) sporontocidal to P. vivax in An. dirus and An. minimus An. dirus oocyst prevalence An. dirus oocyst intensity LC 25 = 38.1 ng/ml LC 5 = 22.1 ng/ml Oocyst prevalence in An. dirus χ 2 = 29.52, P < reps = 6, n = 285 χ 2 = 17.9, P < reps = 6, n = 300 Oocyst intensity per An. dirus P = , n = 156 P = , n = 178 LC 25 = 11.3 ng/ml LC 5 = 6.7 ng/ml Oocyst prevalence in An. minimus An. minimus oocyst prevalence χ2 = 21.72, P < reps = 5, n = 172 χ2 = 12.93, P = reps = 5, n = 235 Oocyst intensity per An. minimus An. minimus oocyst intensity P = , n = 60 P < , n = 139 (Kobylinski et al. 2017a)
21 Ivermectin inhibits P. berghei liver stage development in mice 10 mg/kg 10 mg/kg Repeat ivermectin MDA trial (RIMDAMAL) - Burkina Faso - Ivermectin (150 µg/kg) given to >90 cm (>15kg) x6 MDAs in 18 weeks yo monitored for clinical malaria (Mendes et al. 2017) Significant Findings: - Increase in children with no P. falciparum infection - Delay to first P. falciparum infection - Ivermectin treated children were less likely to develop P. falciparum clinical malaria!!!
22 Ivermectin MDA Field Study in Thailand Collaboration between Mahidol University and AFRIMS - Dr. Jetsumon Sattabongkot Prachumsri (Principal Investigator) Field site Rubber plantations in southern Thailand Assess parameters of malaria transmission: Entomological (population age structure 1, vector composition and density, sporozoite rate) Epidemiological (malaria prevalence 1 and incidence, drug-resistant parasite ratio, and anemia) Funded by Congressionally Directed Medical Research Program Peer Reviewed Medical Research Program (W81XWH )
23 Acknowledgements Ivermectin LC 50 and P. vivax Sporogony Assays: Malaria patients for donating P. vivax samples Thailand Malaria clinic staff in Tak Province for their support obtaining P. vivax samples AFRIMS Department of Entomology Malariology, Insectary, and Vector Biology & Control sections for field and laboratory support Ivermectin & Eurartesim Study: Volunteers for their participation Mahidol University Healthy Volunteer Ward staff for clinical trial support AFRIMS Department of Entomology Insectary, Malariology, and Vector Biology & Control sections and Joi Larson for laboratory support Funding Disclaimer Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR UNCLASSIFIED 23
Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles
DOI 1.1186/s12936-17-1923-8 Malaria Journal RESEARCH Open Access Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles Kevin C. Kobylinski 1,2*, Ratawan Ubalee 1, Alongkot
More informationIvermectin for malaria transmission control
Ivermectin for malaria transmission control Technical consultation meeting report WHO Headquarters Geneva 16 September 2016 Presentation outline Background Rationale for the technical consultation Objectives
More informationKraichat.tan@mahidol.ac.th 1 Outline Vector Borne Disease The linkage of CC&VBD VBD Climate Change and VBD Adaptation for risk minimization Adaptation Acknowledgement: data supported from WHO//www.who.org
More informationIvermectin susceptibility, sporontocidal effect, and inhibition of time to re feed in the Amazonian malaria vector Anopheles darlingi
DOI 10.1186/s12936-017-2125-0 Malaria Journal RESEARCH Open Access Ivermectin susceptibility, sporontocidal effect, and inhibition of time to re feed in the Amazonian malaria vector Anopheles darlingi
More informationA review of Filariasis
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Review Article Volume 5, Issue 2-2019 DOI: http://dx.doi.org/10.22192/ijcrms.2019.05.02.005
More informationDrug therapy of Filariasis. Dr. Shareef sm Asst. professor pharmacology
Drug therapy of Filariasis Dr. Shareef sm Asst. professor pharmacology Signs and symptoms Lymphatic filariasis Fever Inguinal or axillary lymphadenopathy Testicular and/or inguinal pain Skin exfoliation
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT IVOMEC Injection for Pigs 10 mg/ml 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Ivermectin
More informationModule 1. Introduction to Targeted Neglected Tropical Diseases (NTDs)
TARGETED FOR CONTROL OR Module 1. Introduction to Targeted Neglected Tropical Diseases (NTDs) Overview Road map to NTDs targeted for Preventive Chemotherapy (PC) Disease specific epidemiology and control
More informationDifferential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus
Derua et al. Parasites & Vectors (2015) 8:130 DOI 10.1186/s13071-015-0735-3 RESEARCH Open Access Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus
More informationDrug Discovery: Supporting development of new drugs to treat global parasitic diseases
Drug Discovery: Supporting development of new drugs to treat global parasitic diseases UC Santa Cruz Bio 117 Feb. 23, 2016 Judy Sakanari Center for Parasitic Diseases UC San Francisco Parasitic Diseases,
More informationVector Control in emergencies
OBJECTIVE Kenya WASH Cluster Training for Emergencies Oct 2008 3.06 - Vector Control in emergencies To provide practical guidance and an overview of vector control in emergency situations It will introduce
More informationRESIDUAL EFFECT OF 10% BIFENTHRIN WP ON MOSQUITOES, AND COMMUNITY ACCEPTANCE, IN EASTERN THAILAND
RESIDUAL EFFECT OF % BIFENTHRIN WP RESIDUAL EFFECT OF % BIFENTHRIN WP ON MOSQUITOES, AND COMMUNITY ACCEPTANCE, IN EASTERN THAILAND Narumon Komalamisra, Raweewan Srisawat, Chamnarn Apiwathanasorn, Yudthana
More informationERG on multidrug-resistant P. falciparum in the GMS
ERG on multidrug-resistant P. falciparum in the GMS Minutes of ERG meeting Presented by D. Wirth, Chair of the ERG Geneva, 22-24 March 2017 MPAC meeting Background At the Malaria Policy Advisory Committee
More informationIvermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination
Chaccour et al. Malaria Journal 2013, 12:153 CASE STUDY Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination Open Access Carlos J Chaccour 1,2*, Kevin C
More informationA splendid gift from the Earth: the origins & impact of Avermectin
A splendid gift from the Earth: the origins & impact of Avermectin Satoshi Ōmura (M.J.A) Max Tishler Professor of Chemistry Wesleyan University (USA) & Distinguished Emeritus Professor Kitasato Institute
More informationModule 6. Monitoring and Evaluation (M&E)
Overview 1) Current situation on NTD drug resistance: Accelerating work in NTDs and lessons from livestock. Reports of reduced efficacy in NTDs: evidence to date. Causes of reduced efficacy other than
More informationUnderstanding Epidemics Section 3: Malaria & Modelling
Understanding Epidemics Section 3: Malaria & Modelling PART B: Biology Contents: Vector and parasite Biology of the malaria parasite Biology of the anopheles mosquito life cycle Vector and parasite Malaria
More informationBASELINE INFORMATION FOR THE IMPLEMENTATION OF INDOOR RESIDUAL SPRAYING: THE NIGERIA EXPERIENCE
BASELINE INFORMATION FOR THE IMPLEMENTATION OF INDOOR RESIDUAL SPRAYING: THE NIGERIA EXPERIENCE Dr. Sam. Awolola Public Health Entomologist HOD Public, Nigerian Institute of Medical Research, Lagos Sector
More informationIntestinal parasitic infections are a serious
Paediatrica Indonesiana VOLUME 54 March NUMBER 2 Original Article Albendazole alone vs. albendazole and diethylcarbamazine combination therapy for trichuriasis Windya Sari Nasution, Muhammad Ali, Ayodhia
More informationDrug combinations against soiltransmitted
Jennifer Keiser Helminth Drug Development Unit Department of Medical Parasitology and Infection Biology Swiss TPH Winter Symposium 2017 Helminth Infection from Transmission to Control Drug combinations
More informationBIO Parasitology Spring 2009
BIO 475 - Parasitology Spring 2009 Stephen M. Shuster Northern Arizona University http://www4.nau.edu/isopod Lecture 10 Malaria-Life Cycle a. Micro and macrogametocytes in mosquito stomach. b. Ookinete
More informationSummary of the Eighteenth Meeting of the International Task Force for Disease Eradication (II) April 6, 2011
Summary of the Eighteenth Meeting of the International Task Force for Disease Eradication (II) April 6, 2011 The Eighteenth Meeting of the International Task Force for Disease Eradication (ITFDE) was convened
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ERAQUELL 18.7 mg/g Oral Paste (AT, BE, DE, EL, FI, FR, IT, IR, LU, NL, UK) ERAQUELL vet. 18.7 mg/g Oral Paste (NO, SE) EQUIMEL
More informationElephantiasis. C h r i s t i a n H e s s. N u t r i t i o n R o n V e r n o n
Elephantiasis C h r i s t i a n H e s s N u t r i t i o n 1 0 2 0 R o n V e r n o n 11-29-11 Elephantiasis Elephantiasis or Lymphatic Filariasis is defined by The Journal of Veterinary Medicine Series,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Revised: December 2011 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Dectomax 10 mg/ml Solution for Injection for Pigs (UK) Zearl 10 mg/ml Solution for Injection for Pigs
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animec 5 mg/ml Pour-on Solution for Cattle 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Ivermectin 5 mg/ml
More informationMOXIDECTIN SPOT-ON SOLUTION FOR KITTENS AND SMALL CATS. 280 mg/ml FLURALANER 14 mg/ml MOXIDECTIN Also contains: 339 mg/ml DIMETHYLACETAMIDE (solvent)
Product Name: BRAVECTO PLUS FLEA, TICK AND WORM 112.5 MG FLURALANER AND 5.6 MG MOXIDECTIN SPOT-ON SOLUTION FOR KITTENS AND SMALL CATS APVMA Approval No: 85418/113229 Label Name: BRAVECTO PLUS FLEA, TICK
More informationdiscover the nextgeneration of flea & tick protection NEW TASTY CHEW ONE CHEW ONCE A MONTH
discover the nextgeneration of flea & tick protection KILLS FLEAS KILLS TICKS ONE CHEW ONCE A MONTH TASTY CHEW NEW Now there s a new oral treatment that offers effective flea AND tick control on dogs for
More informationMalaria parasites: virulence and transmission as a basis for intervention strategies
Malaria parasites: virulence and transmission as a basis for intervention strategies Matthias Marti Department of Immunology and Infectious Diseases Harvard School of Public Health The global malaria burden
More informationIsrael Journal of Entomology Vol. XXIII(1989) pp
Israel Journal of Entomology Vol. XXIII(1989) pp. 51-57 THE PROSPECT OF BACILLUS THURINGIENSIS VAR. ISRAELENSIS AND BACILLUS SPHAERICUS IN MOSQUITO CONTROL IN THAILAND SOMSAK PANTUWATANA Department of
More informationMedical and Veterinary Entomology
Medical and Veterinary Entomology An eastern treehole mosquito, Aedes triseriatus, takes a blood meal. Urbana, Illinois, USA Alexander Wild Photography Problems associated with arthropods 1) Psychological
More informationA. Effect upon human culture 1. Control of malaria has contributed to world=s population explosion 2. Africans brought to U.S.
VI. Malaria A. Effect upon human culture 1. Control of malaria has contributed to world=s population explosion 2. Africans brought to U.S. because they were resistant to malaria & other diseases 3. Many
More informationFor the treatment and prevention of infections caused by:
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYDECTIN 0.1 % W/V ORAL SOLUTION for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active substance Moxidectin
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animec Super Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance(s):
More informationAdministration of ivermectin to peridomestic cattle: a promising approach to target the residual transmission of human malaria
DOI 10.1186/s12936-015-1001-z Malaria Journal RESEARCH Open Access Administration of ivermectin to peridomestic cattle: a promising approach to target the residual transmission of human malaria Hermann
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cydectin 1% w/v Injectable Solution for Sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Moxidectin Excipients
More informationA Parasiticide for the Treatment and Control of Internal and External Parasites of Cattle and Swine
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com IVOMEC 1% INJECTION FOR CATTLE AND SWINE Merial (ivermectin)
More informationEcology & Evolutionary Biology 4274 Lecture Exam #3. Nematoda, Misc. phyla, Arthropoda, ecology and evolution December 10, 2014
Name 1 Ecology & Evolutionary Biology 4274 Lecture Exam #3 Nematoda, Misc. phyla, Arthropoda, ecology and evolution December 10, 2014 Read through the exam once before you begin. Read the questions CAREFULLY;
More informationIntegrated Resistance Management in the control of disease transmitting mosquitoes
Pan Africa Malaria Vector Control Conference 25 29 October 2009, Zamani Zanzibar Kempinski Hotel Integrated Resistance Management in the control of disease transmitting mosquitoes Mark Hoppé Insecticide
More informationCydectin. Fort Dodge PRODUCT DESCRIPTION
Cydectin Fort Dodge moxidectin Injectable Solution for Beef and Nonlactating Dairy Cattle Antiparasitic Contains 10 mg moxidectin/ml Not for use in female dairy cattle of breeding age, veal calves, and
More informationTHE ABUNDANCE AND INFECTION STATUS OF ANOPHELES MOSQUITOES IN LOUDOUN COUNTY, VIRGINIA
THE ABUNDANCE AND INFECTION STATUS OF ANOPHELES MOSQUITOES IN LOUDOUN COUNTY, VIRGINIA Andrew Lima Clarke (Manassas, VA) Priya Krishnan ODU M.S. candidate (Richmond, VA) Objectives To determine: 1) the
More informationTOLERABILITY OF IVERMECTIN IN GNATHOSTOMIASIS
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH TOLERABILITY OF IVERMECTIN IN GNATHOSTOMIASIS Valai Bussaratid 1, Srivicha Krudsood 2, Udomsak Silachamroon 1 and Sornchai Looareesuwan 1 1 Department of Clinical
More informationManagement of Malaria in Children : Update 2008
G U I D E L I N E S Management of Malaria in Children : Update 2008 INFECTIOUS DISEASES CHAPTER, INDIAN ACADEMY OF PEDIATRICS ABSTRACT Justification: The first guideline on diagnosis and management of
More informationSchool-based Deworming Interventions: An Overview
School-based Deworming Interventions: An Overview Description of the tool: Because helminth (worm) infections can undermine the benefits of school feeding, the WFP encourages deworming interventions and
More informationParasitology Departement Medical Faculty of USU
Malaria Mechanism of infection Parasitology Departement Medical Faculty of USU Introduction Malaria parasites Phylum Order Suborder Family Genus Species : : Apicomplexa : Eucoccidiida : Haemosporida :
More informationLYMPHATIC FILARIASIS WORLD HEALTH ORGANIZATION GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS. A HanDbook for national elimination programmes
WORLD HEALTH ORGANIZATION GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS Lymphatic filariasis: PRACTICAL ENTOMOLOGY LYMPHATIC FILARIASIS A HanDbook for national elimination programmes WORLD HEALTH
More informationAquaculture and human health
Aquaculture and human health Jimmy Turnbull Institute of Aquaculture University of Stirling Scotland UK 1 Introduction zoonosis The transmission of a disease from an animal or nonhuman species to humans.
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Chanimec 10 mg/ml solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Ivermectin
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILBEMAX Film-coated tablets for small cats and kittens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active
More informationWHO/FIU Distr.: Limited English only
WHO/FIU98.194 Distr.: Limited English only WHO/FIL/98.194 English only This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document
More informationCURRICULUM VITAE. Piyanan Taweethavonsawat. University, Bangkok, Thailand M.Sc. (Pathobiology) Faculty of Veterinary Medicine,
CURRICULUM VITAE Personal Data Name Piyanan Taweethavonsawat Date of Birth July 11, 1974 Place of Birth Civil status Nationality Bangkok, Thailand Single Thai Academic qualifications 1991-1996 D.V.M. Faculty
More informationIntroduction to Helminthology
Introduction to Helminthology HELMINTHES (WORMS) - Characteristics Eukaryotic, multicellular animals that usually have digestive, circulatory, nervous, excretory, and reproductive systems. Worms with bilateral
More informationNeglected Zoonoses in Public Health Perspectives
Neglected Zoonoses in Public Health Perspectives Neglected Tropical Diseases Towards control and elimination of Neglected Tropical Diseases FAO-APHCA/OIE/USDA Regional Workshop on Prevention and Control
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILBEMAX Film-coated tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substances:
More informationAlbendazole for the control and elimination of lymphatic filariasis: systematic review
Tropical Medicine and International Health volume 10 no 9 pp 818 825 september 2005 Albendazole for the control and elimination of lymphatic filariasis: systematic review Julia Critchley 1, David Addiss
More informationBalantidium coli Morphology of 2 stages. Balantidium coli
Balantidium coli It causes balantidiasis or balantidial dysentery, is the largest intestinal protozoan of humans. The trophozoite is a ciliated, oval organism 60 X 45 μm or larger. It has a steady progression
More informationMarkers for benzimidazole resistance in human parasitic nematodes?
Markers for benzimidazole resistance in human parasitic nematodes? 1087 ROGER K. PRICHARD* Institute of Parasitology, McGill University, 21111 Lakeshore Road, Ste-Anne-de-Bellevue, Quebec, Canada, H9X
More informationFrom macrocyclic lactones back to tetracyclines: new targets for the antiparasitic treatment in animals and humans
From macrocyclic lactones back to tetracyclines: new targets for the antiparasitic treatment in animals and humans Claudio Genchi Ordinario di Malattie Parassitarie Università degli Studi di Milano Medicinal
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Bimectin 1% w/v Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substances Ivermectin 1.0 % w/v For
More informationSlow Release Ivermectin Formulation for Malaria Control: a Pilot Study in 80-kg Pigs
AAC Accepted Manuscript Posted Online 28 December 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.02104-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 Slow Release Ivermectin
More informationT Mike Lo 1,2 and Maureen Coetzee 1,2*
Lo and Coetzee Parasites & Vectors 2013, 6:184 RESEARCH Open Access Marked biological differences between insecticide resistant and susceptible strains of Anopheles funestus infected with the murine parasite
More informationPerspective Piece Rationale for the Coadministration of Albendazole and Ivermectin to Humans for Malaria Parasite Transmission Control
Am. J. Trop. Med. Hyg., 91(4), 2014, pp. 655 662 doi:10.4269/ajtmh.14-0187 Copyright 2014 by The American Society of Tropical Medicine and Hygiene Perspective Piece Rationale for the Coadministration of
More informationInfecting Anopheles stephensi With Rodent Malaria Parasites Alida Coppi & Photini Sinnis
Infecting Anopheles stephensi With Rodent Malaria Parasites Alida Coppi & Photini Sinnis A. Reagents: 1. DMEM or RPMI DMEM (4.5g/L glucose) RPMI 1640 Cellgro #MT-10-017-CM Cellgro #MT-10-040-CM 2. Giemsa
More informationThe Biology and Control of Human Onchocerciasis Prof. Emeritus Ed Cupp
The Biology and Control Professor Emeritus, Ed Cupp Vector Biology Laboratory Depart. of Entomology & Plant Pathology Auburn University, Auburn, AL 1 Life cycle of Onchocerca volvulus*, the causative agent
More informationANNEX I. Marketing Authorisation Holder (Name and address): Reference Member State:
ANNEX I LIST OF THE PHARMACEUTICAL FORMS, STRENGTHS, ROUTES OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES OF THE VETERINARY MEDICINAL PRODUCT IN THE MEMBER STATES ANNEX I Marketing Authorisation Holder
More informationChapter 9. General discussion
Chapter 9 General discussion Chapter 9 General Discussion Ever since the inception of research into human oesophagostomiasis in northern Ghana and Togo just over two decades ago, Oesophagostomum infection
More informationPRINCIPAL INVESTIGATOR: Dr. Jetsumon (Sattabongkot) Prachumsri
AD (Leave blank) Award Number: W81XWH-07-2-0090 TITLE: Proteomic Study of Human Malaria Parasite Plasmodium Vivax Liver Stages for Development of Vaccines and Drugs PRINCIPAL INVESTIGATOR: Dr. Jetsumon
More informationFOR LAGOS STATE UNIVERSITY WEBSITE. Academic Staff Bio Data
FOR LAGOS STATE UNIVERSITY WEBSITE Academic Staff Bio Data 1. Name (with title(s): DR. (MRS.) OKWA Omolade 2. Pone Number: 08028313362 E mail address: Okwaomolade @ hotmail. com Omolade. Okwa @ lasunigeria.
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT ZANTEL 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Per tablet Praziquantel 50.0 mg Fenbendazole 500.0 mg
More informationTransmission success of the malaria parasite Plasmodium mexicanum into its vector: role of gametocyte density and sex ratio
Transmission success of the malaria parasite Plasmodium mexicanum into its vector: role of gametocyte density and sex ratio 575 J. J. SCHALL* Department of Biology, University of Vermont, Burlington, Vermont
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Milpro 16 mg/40 mg film-coated tablets for cats Milpro Vet. 16 mg/40 mg film-coated tablets for cats (IT, DK) 2. QUALITATIVE
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Acomec 10 mg/ml Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for injection contains: Active
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Equimax Tabs Vet, 150 mg / 20 mg, Chewable tablet for Horses
SUMMARY OF PRODUCT CHARACTERISTICS Revised: June 2013 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equimax Tabs 150 mg / 20 mg Chewable tablet for Horses For DK, SE, FI, IS, NO : Equimax Tabs Vet, 150 mg
More informationEmerging Infections and the Ecotone. Cover: Emerging Zoonoses and Pathogens of Public Health Concern
Emerging Infections and the Ecotone Cover: Emerging Zoonoses and Pathogens of Public Health Concern To learn more, log on to: www.medicalecology.org An ecotone is a narrow transition zone between one
More informationIn cattle: For the treatment of infections with the following parasites
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Kilo-mec 0.5 % Pour-On Solution for Cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains: Active substance Ivermectin 5 mg Excipients
More informationTHE CONTROL AND SURVEILLANCE OF FILARIASIS IN HAINAN PROVINCE, CHINA
FILARIASIS IN HAINAN, PR CHINA THE CONTROL AND SURVEILLANCE OF FILARIASIS IN HAINAN PROVINCE, CHINA Hu Xi-min, Wang Shan-qing, Huang Jie-min, Lin Shaoxiong, Tong Chongjin, Li Shanwen and Zhen Wen Hainan
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Milprazon 16 mg/40 mg film-coated tablets for cats weighing at least 2 kg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Milprazon 16 mg/40 mg film-coated tablets for cats weighing at least 2 kg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationFIGHTING RESISTANCE SAVING LIVES BY COMBATING INSECTICIDE RESISTANCE IN MOSQUITOES
FIGHTING RESISTANCE SAVING LIVES BY COMBATING INSECTICIDE RESISTANCE IN MOSQUITOES WHAT IS INSECTICIDE RESISTANCE? Insecticide resistance develops when genetic mutations allow a small proportion of an
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Equest Oral Gel, 18,92 mg/g, Oral Gel for Horses and Ponies
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equest Oral Gel, 18,92 mg/g, Oral Gel for Horses and Ponies (Sweden: Cydectin Vet) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationCreating a global community for clinical drug repurposing and development. Leonard Sacks Center for drug evaluation and research FDA
Creating a global community for clinical drug repurposing and development Leonard Sacks Center for drug evaluation and research FDA Neglected tropical diseases 1) Repurposing and developing new drugs 2)
More informationVECTORS AND DISEASE. LTC Jason H. Richardson Walter Reed Army Institute of Research. Sand flies Ticks. Mosquitoes. Fleas. Chigger Mites Lice.
VECTORS AND DISEASE Sand flies Ticks Mosquitoes Fleas Chigger Mites Lice Tsetses LTC Jason H. Richardson Walter Reed Army Institute of Research HIT LIST RISK Predeployment, area specific, risk assessment.
More informationHEARTWORM DISEASE AND THE DAMAGE DONE
HEARTWORM DISEASE AND THE DAMAGE DONE Stephen Jones, DVM There are now more months of the year where environmental conditions favor mosquito survival and reproduction. Warmer temperatures Indoor environments
More informationBlood protozoan: Plasmodium
Blood protozoan: Plasmodium The causative agent of including Plasmodium vivax P. falciparum P. malariae P. ovale. malaria in humans:four species are associated The Plasmodium spp. life cycle can be divided
More informationBlood protozoan: Plasmodium
Blood protozoan: Plasmodium Dr. Hala Al Daghistani The causative agent of including Plasmodium vivax P. falciparum P. malariae P. ovale. malaria in humans: four species are associated The Plasmodium spp.
More informationUpdate on antimalarial drug efficacy and resistance in the GMS
Update on antimalarial drug efficacy and resistance in the GMS Drug Efficacy and Response Unit MPAC meeting 17-19 October 2018 Update on artemisinin-resistance markers Relation between partial artemisinin
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationM Correia, D Amonkar, P Audi, C Bhat, P Cruz, N Mitta, A Pednekar, P Kurane
ISPUB.COM The Internet Journal of Surgery Volume 25 Number 2 Filariasis In The Arm A Diagnostic Enigma! M Correia, D Amonkar, P Audi, C Bhat, P Cruz, N Mitta, A Pednekar, P Kurane Citation M Correia, D
More informationBENDEX Plus Tablets (Ivermectin + Albendazole)
Published on: 22 Sep 2014 BENDEX Plus Tablets ( + ) Composition BENDEX Plus Tablets Each uncoated tablet contains:, BP...6 mg, IP...400 mg Dosage Form Tablet Pharmacology Pharmacodynamics The principal
More informationRefractoriness of Culex sitiens to Experimental Infection with Nocturnal Subperiodic Brugia malayi
J Trop Med Parasitol. 2009;32:82-6. RESEARCH NOTE Available online at www.ptat.thaigov.net Refractoriness of Culex sitiens to Experimental Infection with Nocturnal Subperiodic Brugia malayi Samrerng Prummongkol
More informationParasitology PAR 311
Parasitology PAR 311 Basic Information Program Title Bachelor of Medicine and Surgery; MB,BCh Department Offering the Course Parasitology Academic Year / Level Third year Date of Specification Approval
More informationCorallopyronin A: a new anti-filarial drug. Kenneth Pfarr Institute for Medical Microbiology, Immunology and Parasitology
Corallopyronin A: a new anti-filarial drug Kenneth Pfarr Institute for Medical Microbiology, Immunology and Parasitology PEG, Weimar, 17 th October, 2014 Filariasis ~150 million people infected >1.3 billion
More informationNEWSLETTER. ACTION AGAINST WORMS RE-LAUNCHING ACTION AGAINST WORMS
ACTION AGAINST WORMS AUGUST 2007 ISSUE 9 IN THIS ISSUE: Re-launching Action Against Worms What does integrated preventive chemotherapy mean and not mean? Seven reasons why integration is logical The drugs
More informationMedical Parasitology PAR 311
Medical Parasitology PAR 311 Basic Information Program Title Bachelor of Medicine and Surgery; MB,BCh Department Offering the Course Academic Year / Level Date of Specification Approval Total Teaching
More informationActivities of OIE Collaborating Centre for Surveillance and Control of Animal Protozoan Diseases and Protozoan Diseases in wildlife
Activities of OIE Collaborating Centre for Surveillance and Control of Animal Protozoan Diseases and Protozoan Diseases in wildlife Prof. Ikuo Igarashi National Research Center for Protozoan Diseases Obihiro
More informationVulnerability to changes in malaria transmission due to climate change in West Africa
AGU Fall Mee0ng December 4, 2012 Vulnerability to changes in malaria transmission due to climate change in West Africa Teresa K. Yamana & Elfa0h A.B. Eltahir MIT Dept. of Civil & Environmental Engineering
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NexGard 11 mg chewable tablets for dogs 2-4 kg NexGard 28 mg chewable tablets for dogs > 4-10 kg NexGard 68 mg chewable
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationINDONESIA COUNTRY REPORT
INDONESIA COUNTRY REPORT MALARIA ENDEMIC AREA BY DISTRICT, SUB-DISTRICT,VILLAGE IN INDONESIA, 1999 NO.OF AREA NO. OF ENDEMIC AREA % DISTRICT 293 167 57.00 SUB.DISTRICT 3794 910 23.99 VILLAGE 64024 4592
More informationEXCEDE Sterile Suspension
VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free
More informationEfficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India
Tropical Medicine and International Health volume 7 no 6 pp 541 548 june 2002 Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India T. R.
More information